A simple plan to take a bite out of malaria

Un peu de #pharma quand même, puisque Sanofi est dans le coup, et doit bien y trouver son intérêt. Lors du développement d’un médicament contre la Malaria par DNDi il y a 10 ans, Sanofi en était déjà, et on pouvait lire dans Fortune :

Sanofi’s aim was not entirely altruistic, says Bernard Pécoul, executive director of DNDi, a doctor and public health specialist who spearheaded the antimalaria project. “It’s good for their image,” he says, “but it will also help with the penetration of these countries’ markets.”

Mais aussi :

[…] a nonprofit organization in Geneva, Drugs for Neglected Diseases Initiative (DNDi), had figured out a way to combine the two antimalaria drugs and was looking for a corporate partner to conduct clinical trials and market and produce the drug on a large scale. “It was the marriage of both of our needs,” says Robert Sebbag, a vice president for Sanofi.

Source : ▻http://archive.fortune.com/2008/02/22/news/international/malaria.fortune/index.htm?section=magazines_fortuneintl

Je me suis intéressé à DNDi à cette époque pour mon mémoire de master sur la question des communs immatériels dans la coopération internationale (inspiré alors du logiciel libre). Une interrogation, posée un peu vite en fin de chapitre : l’open source en matière de recherche médicale est-elle soluble dans les monopoles ?

Si des fois, le texte complet est là (en espagnol). Sur les médicaments, p22-30 :
▻http://gofile.me/2faRd/eKo0ig4JV

EMA Panel Backs First Oral-Only Drug for Deadly Disease
▻https://www.medscape.com/viewarticle/905009

https://img.medscape.com/thumbnail_library/dt_181116_tsetse_fly_800x450.jpg

Fexinidazole was developed by Sanofi-Aventis in partnership with the Drugs for Neglected Diseases initiative (DNDi), a nonprofit drug research and development organization based in Switzerland. Fexinidazole is intended exclusively for markets outside the European Union.

[...]

This is the tenth medicine recommended by the EMA under Article 58, a regulation that allows the CHMP to assess and give opinions on medicines that are intended for use in countries outside the European Union.

“The scientific opinion from the CHMP helps to support regulators in countries where regulatory capacity may be limited, by providing an expert evaluation of the medicine when used in local practice. National regulators can use the CHMP’s scientific assessment to decide on the use of the medicine in their countries,” the EMA explains.